Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

4,802 total articles

Nebius Q4: Why a Long Position Can Ride Capacity Growth Toward $180

Nebius Q4: Why a Long Position Can Ride Capacity Growth Toward $180

Nebius (NBIS) is positioned at the center of the AI compute buildout. A credible jump in annual run-rate to the low billions by year-end and improving GPU-as-a-Service economics create a pathway to $180/share. This trade idea lays out an entry, stop, and targets with a long-term (180 trading days) horizon while calling out execution, margin, and ma…

Remy Cointreau: Patient Entry Into 2026 Value

Remy Cointreau: Patient Entry Into 2026 Value

Remy Cointreau is a high-quality luxury spirits franchise that has struggled with cyclical demand and FX pressure. The underlying brand strength and margin leverage argue for a long position aimed at 2026 realization, but this trade requires patience and a clear stop to manage execution risk.

Buy VKTX on Pullback - Phase-3 Momentum Meets Quiet Accumulation

Buy VKTX on Pullback - Phase-3 Momentum Meets Quiet Accumulation

Viking Therapeutics (VKTX) is a clinical-stage biotech with a GLP-1/GIP-weight loss candidate, VK2735, edging toward a commercial inflection. With the stock trading around $30.75 after a volatile session, elevated short interest and above-average volume suggest institution-level accumulation. This trade idea lays out an entry at $30.75, a stop at $…

Why OpenAI's Valuation Squeeze Makes Microsoft a Tactical Buy Now

Why OpenAI's Valuation Squeeze Makes Microsoft a Tactical Buy Now

Microsoft's mix of cloud scale, strong free cash flow and favorable AI positioning make it an attractive buy after a pullback tied to headlines around OpenAI's valuation. The company trades at ~25x earnings with $77B of free cash flow and a $2.98T market cap. Technicals look oversold while macro AI capex remains a tailwind. Trade plan included for …

Gray Media: Positioning for a 2026 Political Ad Lift

Gray Media: Positioning for a 2026 Political Ad Lift

Gray Media owns the largest portfolio of local TV stations in the U.S., and its expanding Spanish-language footprint plus upcoming sports and political programming create a clear revenue lever for 2026. Valuation metrics look cheap at the equity level, but leverage is high. This trade targets a re-rating into the mid-$6s as political and sports ad …

Buy the Dip, Lightly: RGNX Looks Priced for a Binary Safety Re-Run

Buy the Dip, Lightly: RGNX Looks Priced for a Binary Safety Re-Run

REGENXBIO (RGNX) is a clinical-stage AAV gene therapy company that traded lower after the FDA placed clinical holds on RGX-111 and RGX-121 following a reported neoplasm case. At $8.33 and a market cap near $422M, the stock appears to price in meaningful program risk. I am cautiously bullish: enter a staged long with tight risk control and a target …

Chipotle: Reasonable Price Today, Wait for Traffic Proof Before Upsizing

Chipotle: Reasonable Price Today, Wait for Traffic Proof Before Upsizing

Chipotle (CMG) looks neither deeply undervalued nor richly expensive. The shares trade near $35.84 with a ~30-31x P/E and strong return metrics, but 2025 traffic weakness and margin trade-offs in 2026 mean upside depends on re-accelerating visits. A measured, mid-term buy-on-weakness approach with a defined stop and target captures upside if traffi…

Buy the Dip: Neurocrine Is More Than Ingrezza - A 180-Day Trade

Buy the Dip: Neurocrine Is More Than Ingrezza - A 180-Day Trade

Neurocrine (NBIX) sold off after below-expectation Ingrezza guidance, but the underlying business remains healthy: Ingrezza grew to $2.51B, Q4 sales topped $805.5M, and the company generates meaningful free cash flow. This trade idea buys the weakness with a clear stop and a 180-trading-day target that prices in recovery plus pipeline upside.

Sana Biotechnology: A high-risk, asymmetric swing trade on a biotech with a promising fusogen readout

Sana Biotechnology: A high-risk, asymmetric swing trade on a biotech with a promising fusogen readout

Sana (SANA) is a speculative long setup that pays to be small and patient. The company’s fusogen in vivo gene-editing work (published in Nature Biotechnology) is a real scientific milestone; the stock is cheap relative to upside if that program wins, but Sana faces cash burn, prior dilution and active litigation. Trade size accordingly and use a ha…

Why a New Braves Media Push Could Be a Short Opportunity

Why a New Braves Media Push Could Be a Short Opportunity

Atlanta Braves Holdings (BATRA) sits at a premium valuation with negative free cash flow and meaningful leverage. Recent options flow and Liberty-related restructuring chatter raise the odds management tests a direct-to-consumer or new local-media approach. If that happens, the company could face higher capex, rights costs, and margin pressure — an…

WEX: Cheap on the Numbers, Expensive on Strategy - A Tactical Long

WEX: Cheap on the Numbers, Expensive on Strategy - A Tactical Long

WEX Inc. looks materially undervalued on cash flow and earnings multiples relative to its growth profile, but recent revenue softness, activist pressure and execution gaps in Mobility and Corporate Payments mean this is a trade, not a buy-and-forget. Enter a measured long at current levels with a firm stop and a target near the 52-week high - a mid…